A Phase IB, Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function (Genentech, Inc. GP27839).
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Vismodegib (Primary)
- Indications Liver cancer; Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 01 Jul 2017 Results published in the Cancer Chemotherapy and Pharmacology
- 06 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov.